We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
+14.25%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$966M
AUM Growth
+$269M
(+39%)
Cap. Flow
+$319M
Cap. Flow
% of AUM
33.08%
Top 10 Holdings %
Top 10 Hldgs %
49.6%
Holding
104
New
32
Increased
25
Reduced
14
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Smith & Nephew
SNN
|
+$27.6M |
| 2 |
Rigel Pharmaceuticals
RIGL
|
+$20.3M |
| 3 |
SI-BONE Inc
SIBN
|
+$18.8M |
| 4 |
Natera
NTRA
|
+$14.1M |
| 5 |
Jasper Therapeutics
JSPR
|
+$13.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVRx
CVRX
|
+$18.6M |
| 2 |
Vericel Corp
VCEL
|
+$16.9M |
| 3 |
Eli Lilly
LLY
|
+$14.3M |
| 4 |
HCA Healthcare
HCA
|
+$8.29M |
| 5 |
Krystal Biotech
KRYS
|
+$8.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.2% |
| 2 | Consumer Staples | 1.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
TG Therapeutics
TGTX
$7.62B
| $11.3M | 1.17% |
750,300
+512,300
| +215% | +$7.78M |
|
27
Neuropace
NPCE
$477M
| $11.3M | 1.17% |
2,428,714
+59,711
| +3% | +$229K |
|
|
28
Vericel Corp
VCEL
$2.29B
| $9.57M | 0.99% |
326,449
-582,548
| -64% | -$16.9M |
|
29
Lantheus
LNTH
$6.6B
| $9.39M | 0.97% |
+113,700
| New | +$7.33M |
|
30
Iovance Biotherapeutics
IOVA
$2.72B
| $8.86M | 0.92% |
+1,449,777
| New | +$10M |
|
|
BCYC
31
Bicycle Therapeutics
BCYC
$277M
| $8.76M | 0.91% |
411,800
+153,400
| +59% | +$3.85M |
|
|
INBX
32
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $8.27M | 0.86% |
438,002
-40,300
| -8% | -$937K |
|
33
Tandem Diabetes Care
TNDM
$1.28B
| $8.26M | 0.85% |
203,300
-109,200
| -35% | -$4.52M |
|
34
4D Molecular Therapeutics
FDMT
$547M
| $8.07M | 0.84% |
469,400
+214,700
| +84% | +$4.17M |
|
35
NovoCure
NVCR
$1.85B
| $7.82M | 0.81% |
+130,000
| New | +$10.4M |
|
36
Viking Therapeutics
VKTX
$3.88B
| $7.66M | 0.79% |
+460,000
| New | +$4.75M |
|
|
ETNB
37
DELISTED
89bio
ETNB
| $7.52M | 0.78% |
494,000
+115,000
| +30% | +$1.5M |
|
38
C4 Therapeutics
CCCC
$401M
| $7.5M | 0.78% |
2,387,020
-53,823
| -2% | -$317K |
|
|
THER
39
DELISTED
THERATECHNOLOGIES INC COM
THER
| $7.36M | 0.76% |
9,090,511
+291,386
| +3% | +$236K |
|
|
40
Krystal Biotech
KRYS
$9.57B
| $6.82M | 0.71% |
85,179
-103,038
| -55% | -$8.09M |
|
41
Syndax Pharmaceuticals
SNDX
$1.76B
| $6.81M | 0.71% |
322,600
+102,600
| +47% | +$2.55M |
|
42
GeneDx Holdings
WGS
$2.06B
| $6.55M | 0.68% |
+543,636
| New | +$7.25M |
|
43
Alkermes
ALKS
$8.15B
| $6.48M | 0.67% |
+230,000
| New | +$6.27M |
|
|
NARI
44
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.26M | 0.65% |
101,450
-123,100
| -55% | -$7.39M |
|
|
NUVL
45
DELISTED
Nuvalent
NUVL
| $6.18M | 0.64% |
+236,900
| New | +$7.01M |
|
|
KRTX
46
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.13M | 0.63% |
+33,740
| New | +$6.45M |
|
47
BridgeBio Pharma
BBIO
$16.1B
| $6.04M | 0.63% |
+364,000
| New | +$4.24M |
|
48
Mirum Pharmaceuticals
MIRM
$5.82B
| $5.81M | 0.6% |
+242,000
| New | +$5.52M |
|
49
Travere Therapeutics
TVTX
$6.05B
| $5.28M | 0.55% |
+234,600
| New | +$4.99M |
|
50
Keros Therapeutics
KROS
$201M
| $5.22M | 0.54% |
122,316
-110,800
| -48% | -$5.6M |
|
Similar funds
TW
M
SG
BL
FFA
GWM
Q
SIM
Soleus Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Soleus Capital Management held 104 positions worth $966M, up 39% from $697M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Soleus Capital Management deployed $319M of net new capital in Q1 2023, opening 32 new positions and adding to 25 existing holdings. Its largest new stake was Smith & Nephew: 970,200 shares worth $27.1M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 97% a quarter earlier, followed by Consumer Staples.
On the sell side, the largest reduction was Vericel Corp, an estimated $16.9M trimmed.
- Soleus Capital Management's largest Q1 2023 buy was Smith & Nephew: 970,200 shares worth $27.1M.
- Soleus Capital Management added most to CVS Health in Q1 2023, an estimated $12.5M increase.
- Soleus Capital Management's biggest Q1 2023 reduction was Vericel Corp, cutting an estimated $16.9M.
- Soleus Capital Management fully exited CVRx in Q1 2023, selling an estimated $18.6M.
- Soleus Capital Management's ten largest holdings make up 50% of its $966M portfolio in Q1 2023.
- Soleus Capital Management opened 32 new positions and closed 27 in Q1 2023.
- Soleus Capital Management's portfolio value rose 39% quarter-over-quarter to $966M.
Based on Soleus Capital Management's 13F filing for Q1 2023, filed 15 May 2023.